Get the Stockscreener App
115.76
0.10%
-0.12
After Hours:
115.60
-0.16
-0.14%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $115.76, with a volume of 5.24M.
It is down -0.10% in the last 24 hours and down -3.06% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$115.88
Open:
$115.88
24h Volume:
5.24M
Relative Volume:
0.79
Market Cap:
$143.64B
Revenue:
$28.80B
Net Income/Loss:
$6.31B
P/E Ratio:
23.06
EPS:
5.02
Net Cash Flow:
$9.37B
1W Performance:
+2.71%
1M Performance:
-3.06%
6M Performance:
-1.41%
1Y Performance:
+46.22%
1-Day Range:
$113.87
$116.25
1-Week Range:
$112.15
$116.25
52-Week Range:
$78.73
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
115.76 | 143.78B | 28.80B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
750.61 | 662.16B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.96 | 429.00B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.42 | 370.61B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.05 | 249.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.61 | 210.04B | 63.43B | 16.42B | 14.72B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead at Morgan Stanley Conference: Strategic Diversification Unveiled - Investing.com
What the Trump Administration Partnership Means for Gilead Sciences Shares in 2025 - Yahoo Finance
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - The Manila Times
Xilio Therapeutics Announces Initiation of Phase 2 Trial - GlobeNewswire
Promising Cancer Drug Shows Partial Responses: Xilio's IL-12 Therapy Advances with $17.5M Gilead Backing - Stock Titan
Wolfspeed, Nvidia, Gilead, SLBM, Corning: What Sparked Heavy After-Hours Trading In These 5 Stocks? - Stocktwits
WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc. - PR Newswire
Gilead Breaks Ground on New US Manufacturing Hub - CHEManager
Biotech Stocks Rise as ACIP Expands RSV Vaccine Recommendations and Gilead Reports Pipeline Progress - geneonline.com
Parkman Healthcare Partners LLC Decreases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Plans Price Increases for HIV Drugs in State-Run AIDS Programs - geneonline.com
Leerink Partners Maintains Buy on Gilead Sciences (GILD) - MSN
Biotech Stocks Rise as ACIP Issues RSV Vaccine Recommendations and Gilead Updates Pipeline Projects - geneonline.com
What earnings revisions data tells us about Gilead Sciences Inc.Quarterly Investment Review & Reliable Volume Spike Alerts - Newser
Biotech Stocks Rise 3.5 Percent as ACIP Updates RSV Vaccine Guidelines and Gilead Reports Positive Trial Results - geneonline.com
Is Gilead Sciences Inc. on track to beat earnings2025 Winners & Losers & Safe Entry Point Identification - خودرو بانک
Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy - Yahoo Finance
What Do Analysts Think About Gilead Sciences (GILD)? - MSN
Momentum divergence signals in Gilead Sciences Inc. chartQuarterly Profit Summary & Weekly Top Performers Watchlists - Newser
FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo - BioPharma Dive
Gilead Announces Partnership With PEPFAR - Contract Pharma
Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries - BioSpace
Rx Rundown: Novartis, Gilead Sciences, Remedy Meds and more - Medical Marketing and Media
What to expect from Gilead Sciences Inc. in the next 30 daysMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
Gilead breaks ground on AI-enabled US manufacturing hub - European Pharmaceutical Review
Gilead Sciences’ Strategic Expansion in HIV Prevention and Global Access: Assessing Long-Term Investment Potential - AInvest
Gilead Sciences advances HIV prevention with new US partnership - Yahoo Finance
Price action breakdown for Gilead Sciences Inc.2025 Volatility Report & Long-Term Growth Stock Strategies - Newser
Stock Analysis | Gilead Sciences OutlookA Strong Technical Picture with Mixed Analyst Signals - AInvest
Gilead joins U.S. to expand access to new HIV drug (GILD) - Seeking Alpha
US plans to bring Gilead HIV drug to market in high-burden HIV countries - Reuters
Gilead partners with PEPFAR to expand HIV prevention access - Investing.com
U.S. to bring Gilead’s HIV drug lenacapavir to high-burden countries - Investing.com
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire
US Plans to Bring Gilead HIV Drug to Market in High-Burden HIV Countries - U.S. News & World Report
Gilead Sciences to Offer Lenacapavir at Cost for Global HIV Prevention - Devdiscourse
Gilead at Wells Fargo Conference: Strategic Growth and Challenges - Investing.com
Gilead Sciences breaks ground on new manufacturing hub - The Pharma Letter
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire
Gilead begins construction of new manufacturing centre in US - World Pharmaceutical Frontiers
Real-World Experiences of People Living with HIV Prioritizing Their Well-Being - Gilead Sciences
'I can't wait to see where we go': Gilead launches $32 billion U.S. investment with new Foster City building - The Business Journals
Gilead Breaks Ground on Pharmaceutical Development & Manufacturing Technical Development Center - Contract Pharma
Gilead Sciences describes new Mpro inhibitors for SARS-CoV-2 - BioWorld MedTech
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV - FinancialContent
Gilead, Amgen kick off facility investments in US - pharmaphorum
Is Gilead Sciences Stock Underperforming the Nasdaq? - Yahoo Finance
Gilead unveils new California manufacturing site, part of $32B US investment - FirstWord Pharma
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy - BioSpace
Is Gilead Sciences Stock Underperforming The Nasdaq? - Barchart.com
GILD Stock Quote Price and Forecast - CNN
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):